{
  "run_id": "e853045d-cf79-4ec4-8d4d-802286157e9e",
  "prompt_variant_id": "934128d7-35f9-4eb3-aaba-b2c097494ca2",
  "api_config_name": "model_gpt_4_turbo",
  "test_case_id": "breast_cancer_her2_positive",
  "start_time": "2025-09-01T16:18:19.957646",
  "end_time": "2025-09-01T16:18:23.298725",
  "duration_ms": 3325.7501125335693,
  "success": true,
  "error_message": "",
  "entities_extracted": 19,
  "entities_mapped": 8,
  "extraction_completeness": 1.1875,
  "mapping_accuracy": 0.7368421052631579,
  "precision": 0.7,
  "recall": 0.875,
  "f1_score": 0.7777777777777777,
  "compliance_score": 1.0,
  "token_usage": 4567,
  "extracted_entities": [
    {
      "text": "HER2-Positive Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.95,
      "source_context": {
        "section": "Conditions",
        "position": "12",
        "context_sentence": "Conditions: HER2-Positive Breast Cancer, Metastatic Breast Cancer",
        "section_name": "conditionsModule",
        "section_type": "conditions",
        "document_id": "unknown"
      }
    },
    {
      "text": "Metastatic Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": null,
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.95,
      "source_context": {
        "section": "Conditions",
        "position": "42",
        "context_sentence": "Conditions: HER2-Positive Breast Cancer, Metastatic Breast Cancer",
        "section_name": "conditionsModule",
        "section_type": "conditions",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-positive metastatic breast cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.95,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": "34",
        "context_sentence": "Histologically confirmed HER2-positive metastatic breast cancer",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "measurable disease",
      "type": "condition",
      "attributes": {
        "status": null,
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": "85",
        "context_sentence": "Measurable disease per RECIST 1.1",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "RECIST 1.1",
      "type": "procedure",
      "attributes": {
        "status": null,
        "value": null,
        "unit": null,
        "temporal_context": null
      },
      "confidence": 0.9,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": "104",
        "context_sentence": "Measurable disease per RECIST 1.1",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "ECOG performance status 0-1",
      "type": "demographic",
      "attributes": {
        "status": null,
        "value": "0-1",
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.95,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": "124",
        "context_sentence": "ECOG performance status 0-1",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "adequate organ function",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.85,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": "151",
        "context_sentence": "Adequate organ function",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Prior treatment with Trastuzumab Deruxtecan",
      "type": "exclusion",
      "attributes": {
        "status": "negative",
        "value": null,
        "unit": null,
        "temporal_context": "past"
      },
      "confidence": 0.95,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": "196",
        "context_sentence": "Prior treatment with Trastuzumab Deruxtecan",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "active brain metastases",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.95,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": "250",
        "context_sentence": "Active brain metastases",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Pregnancy",
      "type": "exclusion",
      "attributes": {
        "status": "negative",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.95,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": "273",
        "context_sentence": "Pregnancy or breastfeeding",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "breastfeeding",
      "type": "exclusion",
      "attributes": {
        "status": "negative",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.95,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": "284",
        "context_sentence": "Pregnancy or breastfeeding",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-targeted therapy",
      "type": "medication",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.95,
      "source_context": {
        "section": "briefSummary",
        "position": "27",
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-positive",
      "type": "biomarker",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.95,
      "source_context": {
        "section": "briefSummary",
        "position": "70",
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "metastatic breast cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.95,
      "source_context": {
        "section": "briefSummary",
        "position": "84",
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "trastuzumab-based therapy",
      "type": "medication",
      "attributes": {
        "status": "past",
        "value": null,
        "unit": null,
        "temporal_context": "past"
      },
      "confidence": 0.95,
      "source_context": {
        "section": "briefSummary",
        "position": "167",
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-Positive",
      "type": "biomarker",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": null
      },
      "confidence": 0.95,
      "source_context": {
        "section": "briefTitle",
        "position": "22",
        "context_sentence": "Study of Novel Therapy in HER2-Positive Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": null,
        "value": null,
        "unit": null,
        "temporal_context": null
      },
      "confidence": 0.95,
      "source_context": {
        "section": "briefTitle",
        "position": "42",
        "context_sentence": "Study of Novel Therapy in HER2-Positive Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-Positive",
      "type": "biomarker",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": null
      },
      "confidence": 0.95,
      "source_context": {
        "section": "officialTitle",
        "position": "43",
        "context_sentence": "A Phase III Study of Novel Targeted Therapy in HER2-Positive Metastatic Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "Metastatic Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": null,
        "value": null,
        "unit": null,
        "temporal_context": null
      },
      "confidence": 0.95,
      "source_context": {
        "section": "officialTitle",
        "position": "67",
        "context_sentence": "A Phase III Study of Novel Targeted Therapy in HER2-Positive Metastatic Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    }
  ],
  "mcode_mappings": [
    {
      "resourceType": "Condition",
      "mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-Positive Breast Cancer",
      "mapping_confidence": 0.95,
      "source_text_fragment": "Entity index 0",
      "mapping_rationale": "Direct match to condition with specific cancer type and biomarker status.",
      "id": "14cc0ddf-fcca-4f76-ab4a-37ddd917f2f0",
      "llm_source_text_fragment": "Entity index 0",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Metastatic Breast Cancer",
      "mapping_confidence": 0.95,
      "source_text_fragment": "Entity index 1",
      "mapping_rationale": "Direct match to condition with specific cancer type indicating metastasis.",
      "id": "198f06f6-906e-41f7-865f-f0cd9eb0c9f2",
      "llm_source_text_fragment": "Entity index 1",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-Positive Metastatic Breast Cancer",
      "mapping_confidence": 0.95,
      "source_text_fragment": "Entity index 2",
      "mapping_rationale": "Direct match to condition with specific cancer type, biomarker status, and metastasis.",
      "id": "7870a598-0e5a-4cae-ae98-4ab73c2c5087",
      "llm_source_text_fragment": "Entity index 2",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "mcode_element": "ECOGPerformanceStatus",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "ecogperformancestatus",
        "display": "ECOGPerformanceStatus"
      },
      "value": "0-1",
      "mapping_confidence": 0.95,
      "source_text_fragment": "Entity index 5",
      "mapping_rationale": "Direct match to ECOG performance status with specified range.",
      "id": "961e4367-335d-4397-b321-103ed8ce3965",
      "llm_source_text_fragment": "Entity index 5",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "Trastuzumab Deruxtecan",
      "mapping_confidence": 0.95,
      "source_text_fragment": "Entity index 7",
      "mapping_rationale": "Direct match to medication name used in cancer treatment.",
      "id": "5299a27d-4ac5-4347-8010-d9deb5588156",
      "llm_source_text_fragment": "Entity index 7",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Active Brain Metastases",
      "mapping_confidence": 0.95,
      "source_text_fragment": "Entity index 8",
      "mapping_rationale": "Direct match to condition indicating specific site of metastasis.",
      "id": "b5d144d6-a23e-4180-91cb-0359c89ef6cd",
      "llm_source_text_fragment": "Entity index 8",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "HER2-targeted therapy",
      "mapping_confidence": 0.95,
      "source_text_fragment": "Entity index 10",
      "mapping_rationale": "Direct match to a category of medication targeting HER2.",
      "id": "83c65d32-9a60-496d-af4c-6ba8933a8236",
      "llm_source_text_fragment": "Entity index 10",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "trastuzumab-based therapy",
      "mapping_confidence": 0.95,
      "source_text_fragment": "Entity index 13",
      "mapping_rationale": "Direct match to a specific type of past medication used in cancer treatment.",
      "id": "eb5397db-baec-4678-87e7-bbc5e6b3c3cb",
      "llm_source_text_fragment": "Entity index 13",
      "source_references": []
    }
  ],
  "validation_results": {
    "valid": true,
    "errors": [],
    "warnings": [],
    "compliance_score": 1.0
  }
}